AnaptysBio, Inc.ANABNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank83
3Y CAGR+15.3%
5Y CAGR+11.2%
Year-over-Year Change
Research and development spending
3Y CAGR
+15.3%/yr
vs +12.1%/yr prior
5Y CAGR
+11.2%/yr
Recent acceleration
Acceleration
+3.2pp
Accelerating
Percentile
P83
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $135.97M | -17.0% |
| 2024 | $163.84M | +17.3% |
| 2023 | $139.62M | +57.2% |
| 2022 | $88.80M | -9.8% |
| 2021 | $98.50M | +23.1% |
| 2020 | $80.03M | -19.4% |
| 2019 | $99.34M | +76.5% |
| 2018 | $56.30M | +81.9% |
| 2017 | $30.94M | +36.8% |
| 2016 | $22.62M | - |